0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Image of the Month—Diagnosis FREE

Arch Surg. 2012;147(6):576. doi:10.1001/archsurg.147.6.576.
Text Size: A A A
Published online

In this patient, more than 100 polyps were seen during esophagogastroduodenoscopy and at least 30 were removed for biopsy. Polyp biopsies showed no evidence of Helicobacter pylori microorganisms or dysplasia, and all were found to be inflammatory polyps of the gastric fundic type. The patient's proton pump inhibitor (PPI) was discontinued. The patient was seen for follow-up 8 months later and reported improvement of symptoms. Repeated esophagogastroduodenoscopy (Figure 3) showed remarkable resolution of the gastric polyps. Results of a colonoscopy performed to evaluate for colonic polyps were negative. Incidentally, multiple gallbladder polyps were found on ultrasonography of the right upper quadrant; the largest gallbladder polyp was 7 mm. The patient was scheduled to have a laparoscopic cholecystectomy to eliminate any possibility of malignancy.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 3. Follow-up esophagogastroduodenoscopy showed the fundus with a few small, scattered, hyperplastic polyps. The remainder of the stomach appeared normal.

Fundic gland polyps (FGPs) are usually smaller than 1 cm and are smooth, glassy, and often transparent in appearance. They are typically found in the fundus and upper body of the stomach. Histologically, they have fundic mucosa with dilated cystic glands, parietal cell protrusions, and parietal cell hyperplasia. Treatment of FGPs is based on the size of the polyps. For those larger than 1 cm, biopsies are performed and PPI use is discontinued. For those between 0.5 and 1.0 cm, biopsies are done. For those smaller than 0.5 cm, surveillance is performed in 3 to 6 months.

The FGPs are usually detected incidentally during endoscopic evaluation for abdominal pain, dyspepsia, or chronic reflux as in our patient. They are the most common gastric polyps in Western countries, found incidentally in 2% of all endoscopic studies.14 They may be sporadic, may occur in association with PPI use, or may be present in patients with familial adenomatous polyposis.1,58 Sporadic and PPI-associated FGPs are believed to have a low malignant potential in contrast to the familial adenomatous polyposis–associated FGPs. The incidence of FGPs has increased owing to the overuse of PPIs in the treatment of acid-related disorders such as gastroesophageal reflux disease, peptic ulcer disease, and H pylori infection; they are associated with PPI use in up to 1.9% of the general population. Increased risk of FGPs was noted with PPI use longer than 1 year (odds ratio = 2.2; 95% CI, 1.3-3.8) as compared with short-term use (odds ratio = 1.0; 95% CI, 0.5-1.8).5 Also, an increased risk of dysplasia in FGPs was suggested in a case-control study involving patients with familial adenomatous polyposis receiving a PPI.5,9

The formation of FGPs is postulated to be a result of hypergastrinemia leading to parietal cell hyperplasia and protrusion into the lumen of the gland. Long-term PPI use is associated with a 4-fold increased risk of FGPs. Several studies have documented that discontinuation of the PPI results in the disappearance of the polyps.7,8 The true clinical significance of these FGPs remains elusive. Further long-term prospective studies are required to elucidate the long-term risks of prolonged PPI use.

Return to Quiz Case.

Correspondence: Izi Obokhare, MD, Department of Surgery, University Hospitals Case Medical Center, 11100 Euclid Ave, Cleveland, OH 44106 (iobokhare@hotmail.com).

Accepted for Publication: July 28, 2011.

Author Contributions:Study concept and design: Obokhare, Santoso, and Ponsky. Acquisition of data: Obokhare and Santoso. Analysis and interpretation of data: Santoso and Coughlan. Drafting of the manuscript: Obokhare, Santoso, and Coughlan. Critical revision of the manuscript for important intellectual content: Obokhare, Santoso, and Ponsky. Administrative, technical, and material support: Obokhare, Santoso, and Coughlan. Study supervision: Ponsky.

Financial Disclosure: None reported.

Carmack SW, Genta RM, Graham DY, Lauwers GY. Management of gastric polyps: a pathology-based guide for gastroenterologists.  Nat Rev Gastroenterol Hepatol. 2009;6(6):331-341
PubMed   |  Link to Article
Freeman HJ. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis.  World J Gastroenterol. 2008;14(9):1318-1320
PubMed   |  Link to Article
Kuipers EJ. Proton pump inhibitors and gastric neoplasia.  Gut. 2006;55(9):1217-1221
PubMed   |  Link to Article
Lodato F, Azzaroli F, Turco L,  et al.  Adverse effects of proton pump inhibitors.  Best Pract Res Clin Gastroenterol. 2010;24(2):193-201
PubMed   |  Link to Article
Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy.  Aliment Pharmacol Ther. 2006;24(9):1341-1348
PubMed   |  Link to Article
Thomson ABR, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors.  World J Gastroenterol. 2010;16(19):2323-2330
PubMed   |  Link to Article
Rubio CA, Befrits R, Osterberg J, Ohd J, Miller ML, Ramel S. Massive fundic gland polyposis in a patient receiving protracted proton-pump inhibitor medication.  Anticancer Res. 2010;30(1):261-263
PubMed
Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors.  Am J Med. 2009;122(10):896-903
PubMed   |  Link to Article
Attard TM, Yardley JH, Cuffari C. Gastric polyps in pediatrics: an 18-year hospital-based analysis.  Am J Gastroenterol. 2002;97(2):298-301
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure 3. Follow-up esophagogastroduodenoscopy showed the fundus with a few small, scattered, hyperplastic polyps. The remainder of the stomach appeared normal.

Tables

References

Carmack SW, Genta RM, Graham DY, Lauwers GY. Management of gastric polyps: a pathology-based guide for gastroenterologists.  Nat Rev Gastroenterol Hepatol. 2009;6(6):331-341
PubMed   |  Link to Article
Freeman HJ. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis.  World J Gastroenterol. 2008;14(9):1318-1320
PubMed   |  Link to Article
Kuipers EJ. Proton pump inhibitors and gastric neoplasia.  Gut. 2006;55(9):1217-1221
PubMed   |  Link to Article
Lodato F, Azzaroli F, Turco L,  et al.  Adverse effects of proton pump inhibitors.  Best Pract Res Clin Gastroenterol. 2010;24(2):193-201
PubMed   |  Link to Article
Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy.  Aliment Pharmacol Ther. 2006;24(9):1341-1348
PubMed   |  Link to Article
Thomson ABR, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors.  World J Gastroenterol. 2010;16(19):2323-2330
PubMed   |  Link to Article
Rubio CA, Befrits R, Osterberg J, Ohd J, Miller ML, Ramel S. Massive fundic gland polyposis in a patient receiving protracted proton-pump inhibitor medication.  Anticancer Res. 2010;30(1):261-263
PubMed
Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors.  Am J Med. 2009;122(10):896-903
PubMed   |  Link to Article
Attard TM, Yardley JH, Cuffari C. Gastric polyps in pediatrics: an 18-year hospital-based analysis.  Am J Gastroenterol. 2002;97(2):298-301
PubMed   |  Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles